PharmaVentures Advises IDT Australia on the Divestment of CMAX Clinical Trial Business to the Japanese Company I'rom Group Co. Ltd. - Seite 2

Through CMAX, its clinical research services business based adjacent to the new Royal Adelaide Hospital in South Australia, IDT also provides full Phase I clinical trials management and delivery, recruitment in specific disease states for Phase II and Phase III trials as well as offering trial packaging, distribution and pharmacy services from the cGMP Boronia facilities.

Click here to see IDT's Press Release

About I'rom 

I'rom Group Co. Ltd is an integrated Japanese healthcare company listed on the Tokyo Stock Exchange. I'rom Group's primary business is the provision of clinical trial site management services as a Site Management Organisation ("SMO"). I'rom Group have been an IDT shareholder since 2013. I'rom Group believes that the acquisition of the CMAX business will help grow profits and help the company and its shareholders through an increased corporate value. Furthermore, I'rom Group will be able to acquire knowledge that will assist in growing the company's existing clinical trial and advanced therapeutics business domains.

- Ends - 

PharmaVentures is a premier transaction advisory firm; a leader in partnering, M&A deals and strategic alliances. 

Our unrivalled bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes them uniquely placed to support your business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

Find out more http://www.pharmaventures.com

Their services include: 

• M&A (divestments, mergers, acquisitions and strategic transactions)
• Strategy (commercialisation, deal strategy, due diligence, market entry)
• Valuation and Positioning (licensing, M&A, fund raising & expert testimonies)
• Licensing (in and out licensing)
• Expert Testimony (patent infringement, deal disagreements, taxation, determining damages)
• Fundraising

Now in its 25th year, PharmaVentures is based in Oxford, UK, and employs over 20 professionals and has associates in N. America, Latin America, and Asia-Pacific.

FOR FURTHER INFORMATION, CONTACT: 
 
Dr Fintan Walton
Chief Executive
PharmaVentures Ltd
[phone]
[e-mail]
Twitter | LinkedIn